Sangamo Therapeutics Inc (SGMO) Holdings Increased by Wells Fargo & Company MN

Wells Fargo & Company MN grew its stake in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 12.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 890,234 shares of the biopharmaceutical company’s stock after buying an additional 100,253 shares during the quarter. Wells Fargo & Company MN owned about 0.88% of Sangamo Therapeutics worth $15,089,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the business. Private Advisor Group LLC bought a new stake in shares of Sangamo Therapeutics in the 3rd quarter worth about $245,000. Russell Investments Group Ltd. grew its holdings in shares of Sangamo Therapeutics by 194.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 105,894 shares of the biopharmaceutical company’s stock worth $1,795,000 after purchasing an additional 69,984 shares during the last quarter. Bourgeon Capital Management LLC bought a new stake in shares of Sangamo Therapeutics in the 3rd quarter worth about $197,000. Handelsbanken Fonder AB grew its holdings in shares of Sangamo Therapeutics by 52.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 545,000 shares of the biopharmaceutical company’s stock worth $9,238,000 after purchasing an additional 188,000 shares during the last quarter. Finally, Handelsinvest Investeringsforvaltning grew its holdings in shares of Sangamo Therapeutics by 25.0% in the 3rd quarter. Handelsinvest Investeringsforvaltning now owns 125,000 shares of the biopharmaceutical company’s stock worth $2,119,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors own 63.13% of the company’s stock.

Sangamo Therapeutics stock opened at $11.78 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.32 and a current ratio of 6.32. Sangamo Therapeutics Inc has a 1 year low of $9.00 and a 1 year high of $27.50. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -16.83 and a beta of 3.10.



Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. The business had revenue of $23.56 million for the quarter, compared to the consensus estimate of $26.96 million. Sangamo Therapeutics had a negative net margin of 88.78% and a negative return on equity of 22.06%. Sangamo Therapeutics’s revenue for the quarter was up 99.5% on a year-over-year basis. During the same period last year, the company posted ($0.15) EPS. On average, analysts forecast that Sangamo Therapeutics Inc will post -0.72 earnings per share for the current year.

Several equities research analysts have recently weighed in on SGMO shares. BidaskClub raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 2nd. Zacks Investment Research raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 14th. ValuEngine lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, September 6th. Guggenheim lowered shares of Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 price objective on the stock. in a report on Friday, November 9th. Finally, JPMorgan Chase & Co. lowered shares of Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $11.00 in a report on Wednesday, November 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $19.71.

In related news, Director H Stewart Parker bought 2,000 shares of the company’s stock in a transaction on Friday, September 7th. The shares were purchased at an average cost of $13.52 per share, for a total transaction of $27,040.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $10.00, for a total transaction of $50,000.00. Following the sale, the chief financial officer now owns 12,250 shares in the company, valued at $122,500. The disclosure for this sale can be found here. Insiders have sold a total of 25,000 shares of company stock worth $334,550 over the last 90 days. Corporate insiders own 1.20% of the company’s stock.

WARNING: This article was published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://dakotafinancialnews.com/2018/12/06/sangamo-therapeutics-inc-sgmo-holdings-increased-by-wells-fargo-company-mn.html.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

See Also: Systematic Risk and Investors

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply